Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Institutes of Health Clinical Center (CC)
Sotio Biotech Inc.
National Cancer Institute (NCI)
MacroGenics
Incyte Corporation
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
Hoffmann-La Roche
University of Virginia
Incyte Corporation
Theratechnologies
AstraZeneca
Xencor, Inc.
Pfizer
University of Florida
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Opna Bio LLC
Genocea Biosciences, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Abramson Cancer Center at Penn Medicine
Celgene
University of Wisconsin, Madison
Santa Maria Biotherapeutics
Virginia Commonwealth University
University of Southern California
Northwestern University
Rutgers, The State University of New Jersey
ImmunoGen, Inc.
Yale University
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mannkind Corporation
Case Comprehensive Cancer Center